4.7 Article

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia

期刊

BLOOD
卷 112, 期 3, 页码 844-847

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-01-135897

关键词

-

资金

  1. Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom

向作者/读者索取更多资源

Among 994 patients with essential thrombocythemia (ET) who were genotyped for the MPLW515UK mutation, 30 patients carrying the mutation were identified (3.0%), 8 of whom also displayed the JAK2V671 F mutation. MPLW515UK patients presented lower hemoglobin levels and higher platelet counts than did wild type (wt) MPL; these differences were highly significant compared with MPLwV JAK2V617F-positive patients. Reduced hemoglobin and increased platelet levels were preferentially associated with the W515L and W515K alleles, respectively. MPL mutation was a significant risk factorformicrovesseldisturbances,suggest- ing platelet hyperreactivity associated with constitutively active MPL; arterial thromboses were increased only in comparison to MPLwtlJAK2wt patients. MPLW515UK patients presented reduced total and erythroid bone marrow cellularity, whereas the numbers of megakaryocytes, megakaryocytic clusters, and small-sized megakaryocytes were all significantly increased. These data indicate that MPLW515/K mutations do not define a distinct phenotype in ET, although some differences depended on the JAK2V617F mutational status of the counterpart.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Hematology

The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms

Jurgen Thiele, Hans Michael Kvasnicka, Attilio Orazi, Umberto Gianelli, Naseema Gangat, Alessandro M. Vannucchi, Tiziano Barbui, Daniel A. Arber, Ayalew Tefferi

Summary: A group of international experts met to update the World Health Organization classification system for hematopoietic tumors and introduced the new International Consensus Classification (ICC) for Myeloid Neoplasms and Acute Leukemias. The focus of this review is on the ICC-2022 category of JAK2 mutation-prevalent myeloproliferative neoplasms (MPNs) and the importance of bone marrow morphology and genetic markers in disease classification and diagnostics.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Article Biophysics

Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT

Ryszard Swoboda, Myriam Labopin, Sebastian Giebel, Thomas Schroeder, Nicolaus Kroeger, Mutlu Arat, Bipin Savani, Alexandros Spyridonidis, Rose-Marie Hamladji, Victoria Potter, Ana Berceanu, Ibrahim Yakoub-Agha, Alessandro Rambaldi, Hakan Ozdogu, Jaime Sanz, Arnon Nagler, Mohamad Mohty

Summary: This study compared two different myeloablative conditioning regimens, FluTBI12 and FB4, before allo-HCT in AML patients. The results showed no significant differences in leukemia-free survival, overall survival, relapse incidence, and non-relapse mortality between the two groups. The incidence of acute and chronic GVHD also showed no statistical differences. In conclusion, FluTBI12 and FB4 are comparable myeloablative regimens for AML patients transplanted in CR1 and CR2.

BONE MARROW TRANSPLANTATION (2023)

Review Pathology

International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms

Umberto Gianelli, Juergen Thiele, Attilio Orazi, Naseema Gangat, Alessandro M. Vannucchi, Ayalew Tefferi, Hans Michael Kvasnicka

Summary: The International Consensus Classification (ICC) of myeloid neoplasms, which was based on the efforts of pathologists, oncologists, and geneticists, aimed to update the 2017 World Health Organization classification system for hematopoietic tumors. The classification of myeloproliferative neoplasms (MPNs) underwent significant modifications, especially in terms of diagnostic methods and criteria.

VIRCHOWS ARCHIV (2023)

Letter Oncology

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis

Paola Guglielmelli, Chiara Maccari, Benedetta Sordi, Manjola Balliu, Alessandro Atanasio, Carmela Mannarelli, Giulio Capecchi, Ilaria Sestini, Giacomo Coltro, Giuseppe Gaetano Loscocco, Giada Rotunno, Eva Angori, Filippo C. Borri, Ayalew Tefferi, Alessandro M. Vannucchi

BLOOD CANCER JOURNAL (2023)

Article Oncology

Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project

Giacomo Coltro, Emanuela Sant'Antonio, Giuseppe A. Palumbo, Francesco Mannelli, Valerio De Stefano, Marco Ruggeri, Elena M. Elli, Roberta Zanotti, Oscar Borsani, Irene Bertozzi, Andrea Duminuco, Silvia Betti, Giuseppe Carli, Fabrizio Cavalca, Ilaria Tanasi, Elisa Rumi, Maria L. Randi, Bruno Garibaldi, Giuseppe G. Loscocco, Paola Guglielmelli, Alessandro M. Vannucchi

Summary: This study provides valuable insights into the efficacy and safety of ruxolitinib in a real-world cohort of Italian patients with myelofibrosis. The results highlight the importance of drug exposure, side effects, and treatment response in determining patient outcomes.

CANCER MEDICINE (2023)

Review Hematology

Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT

Nicola Polverelli, Juan Carlos Hernandez-Boluda, Tomasz Czerw, Tiziano Barbui, Mariella D'Adda, Hans Joachim Deeg, Markus Ditschkowski, Claire Harrison, Nicolaus Martin Kroger, Ruben Mesa, Francesco Passamonti, Francesca Palandri, Naveen Pemmaraju, Uday Popat, Damiano Rondelli, Alessandro Maria Vannucchi, Srdan Verstovsek, Marie Robin, Antonio Colecchia, Luigi Grazioli, Enrico Damiani, Domenico Russo, Jessica Brady, David Patch, Slawomir Blamek, Gandhi Laurent Damaj, Patrick Hayden, Donal P. McLornan, Ibrahim Yakoub-Agha

Summary: Splenomegaly is a common complication in myelofibrosis patients and can negatively impact outcomes of allogeneic hematopoietic cell transplantation (HCT). This Position Paper provides a shared position statement on the management of splenomegaly before HCT. The assessment, prevalence, and clinical significance of splenomegaly are discussed, along with the need for therapeutic intervention. Specific scenarios, such as splanchnic vein thrombosis and COVID-19, are also addressed.

LANCET HAEMATOLOGY (2023)

Article Oncology

Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study

Francesca Palandri, Haifa Kathrin Al-Ali, Paola Guglielmelli, Mike W. Zuurman, Rajendra Sarkar, Vikas Gupta

Summary: Bone marrow fibrosis (BMF) is a negative prognostic factor for myelofibrosis (MF). The JUMP trial investigated the safety and efficacy of the JAK1/JAK2 inhibitor ruxolitinib in symptomatic MF patients. This post hoc analysis found that patients with low-grade fibrosis (LGF) had better response rates and survival estimates compared to patients with high-grade fibrosis (HGF). Early initiation of ruxolitinib therapy was associated with increased response rates in all patients.

CANCERS (2023)

Article Hematology

Orbital Infiltration in a Patient with Waldenstrom Macroglobulinemia: Need for Multidisciplinary Approach and Comparison with the Literature

Riccardo Paggi, Francesca Mariotti, Jessica Mencarini, Silvia Bresci, Irene Campolmi, Filippo Bartalesi, Beatrice Borchi, Luca Nassi, Benedetta Sordi, Alessandro Maria Vannucchi, Alessandro Bartoloni

Summary: The use of specific inhibitory drugs for intracellular signalling pathways is a risk factor for Aspergillus spp. infections in patients with Waldenstrom's macroglobulinaemia. The overlapping clinical manifestations of the two diseases may require different medical specialties.

MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2023)

Editorial Material Hematology

Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement

Giuseppe G. Loscocco, Stefano Ascani, Francesco Mannelli, Magda Zanelli, Giada Rotunno, Raffaella Santi, Alessandro M. Vannucchi

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Article Multidisciplinary Sciences

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia

Gabriele Casirati, Andrea Cosentino, Adele Mucci, Mohammed Salah Mahmoud, Iratxe Ugarte Zabala, Jing Zeng, Scott B. Ficarro, Denise Klatt, Christian Brendel, Alessandro Rambaldi, Jerome Ritz, Jarrod A. Marto, Danilo Pellin, Daniel E. Bauer, Scott A. Armstrong, Pietro Genovese

Summary: Epitope engineering of donor haematopoietic stem/progenitor cells endows haematopoietic lineages with selective resistance to CAR T cells or monoclonal antibodies, without affecting protein function or regulation, enabling the targeting of genes that are essential for leukaemia survival and reducing the risk of tumour immune escape.

NATURE (2023)

Editorial Material Oncology

Acute Myocardial Infarction and Chronic Myeloproliferative Neoplasms Friend and Enemy, Depending on Circumstances

Alessandro Maria Vannucchi, Paola Guglielmelli

JACC: CARDIOONCOLOGY (2023)

Article Medicine, General & Internal

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srdan Verstovsek, Aaron T. Gerds, Alessandro M. Vannucchi, Haifa Kathrin Al-Ali, David Lavie, Andrew T. Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh, Mihaela C. Lazaroiu, Miklos Egyed, Maria Laura Fox, Donal McLornan, Andrew Perkins, Sung -Soo Yoon, Vikas Gupta, Jean -Jacques Kiladjian, Nikki Granacher, Sung-Eun Lee, Luminita Ocroteala, Francesco Passamonti, Claire N. Harrison, Barbara J. Klencke, Sunhee Ro, Rafe Donahue, Jun Kawashima, Ruben Mesa

Summary: This study aimed to compare the clinical effects of momelotinib and danazol in patients with intermediate or high-risk myelofibrosis. The results showed that momelotinib can significantly improve myelofibrosis-associated symptoms, anemia measures, and spleen response compared to danazol, with favorable safety.

LANCET (2023)

Article Oncology

The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients

Tiziano Barbui, Alessandra Carobbio, Juergen Thiele, Naseema Gangat, Elisa Rumi, Alessandro Rambaldi, Alessandro M. Vannucchi, Ayalew Tefferi

Summary: This study applied a parametric Markov model to investigate the impact of incident thrombosis on death or disease progression in patients with polycythemia vera. The results showed that thrombosis was associated with a higher probability of death and had different effects on arterial and venous thrombosis.

BLOOD CANCER JOURNAL (2023)

暂无数据